Taiwan study checks lupus kidney drug safety

NCT ID NCT04645589

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study followed 69 people in Taiwan with lupus nephritis who were newly prescribed the drug Myfortic (mycophenolate sodium). Researchers tracked side effects and reasons for stopping the drug over 12 months. The goal was to understand the drug's safety in this specific population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Myfortic (mycophenolate sodium)
What this could lead to: If the results confirm Myfortic is safe, it may support its continued use for lupus nephritis in Taiwan.
What could go wrong: This was a small, single-arm, observational study with no comparison group, so it cannot prove effectiveness. Results may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS

Contacts and locations

Locations

Novartis Investigative Site

Kaohsiung City, 83301, Taiwan
Novartis Investigative Site

Keelung, 20401, Taiwan
Novartis Investigative Site

Taichung, 407219, Taiwan
Novartis Investigative Site

Taipei, 10002, Taiwan
Novartis Investigative Site

Taipei, 105, Taiwan
Novartis Investigative Site

Taoyuan, 33305, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.